kestine oral lyophilisate 10 milligram
almirall, s.a. - ebastine - oral lyophilisate - 10 milligram
kestine oral lyophilisate 20 milligram
almirall, s.a. - ebastine - oral lyophilisate - 20 milligram
airtal 100mg film-coated tablets. 100 milligram tablets
almirall, s.a. - aceclofenac - tablets - 100 milligram
almogran 12.5 mg film-coated tablet
almirall, s.a. - almotriptan - film-coated tablet - 12.5 milligram(s) - selective serotonin (5ht1) agonists; almotriptan
kestine 20 milligram oral lyophilisate
almirall, s.a. - ebastine - oral lyophilisate - 20 milligram
kestine 10 milligram tablets
almirall, s.a. - ebastine - tablets - 10 milligram
kestine 10 milligram oral lyophilisate
almirall, s.a. - ebastine - oral lyophilisate - 10 milligram
kestine 20mg milligram tablets
almirall, s.a. - ebastine - tablets - 20mg milligram
altabax- retapamulin ointment
almirall, llc - retapamulin (unii: 4mg6o8991r) (retapamulin - unii:4mg6o8991r) - retapamulin 10 mg - altabax® is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14)] . safety in patients younger than 9 months has not been established. to reduce the development of drug-resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs, altabax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. none. risk summary there are no available data on altabax use in pregnant women to inform any drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. retapamulin is negligibly absorbed systemically following topical administration and maternal use is not expected to result in fetal exp
cordran- flurandrenolide cream cordran- flurandrenolide ointment
almirall, llc - flurandrenolide (unii: 8eul29xuqt) (flurandrenolide - unii:8eul29xuqt) - flurandrenolide 0.5 mg in 1 g - cordran® (flurandrenolide, usp) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.